{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:30:53Z","timestamp":1780050653171,"version":"3.53.1"},"reference-count":113,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T00:00:00Z","timestamp":1575417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Internationally there is an escalation of prescription-related overdose deaths, particularly related to benzodiazepine use. As a result, many countries have implemented prescription monitoring programs (PMPs) to increase the regulation of benzodiazepine medications. PMPs centralize prescription data for prescribers and pharmacists and generate alerts to high-doses, risky combinations, or multiple prescribers with the aim to reduce inappropriate prescribing and subsequently the potential of patient harm. However, it has become clear that prescribers have been provided with minimal guidance and insufficient training to effectively integrate PMP information into their decision making around prescribing these medications. Accordingly, this paper discusses how PMPs have given rise to a range of unintended consequences in those who have been prescribed benzodiazepines (BDZs). Given that a gradual taper is generally required to mitigate withdrawal from BDZs, there are concerns that alerts from PMPs have resulted in BDZs being ceased abruptly, resulting in a range of unintended harms to patients. It is argued that best practice guidelines based upon a patient-centered framework of decision-making, need to be developed and implemented, in order to curtail the unintended consequences of PMPs. This paper outlines some key considerations when starting the conversation with patients about their BDZ use.<\/jats:p>","DOI":"10.3390\/jcm8122143","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T03:16:36Z","timestamp":1575515796000},"page":"2143","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Beyond Prescriptions Monitoring Programs: The Importance of Having the Conversation about Benzodiazepine Use"],"prefix":"10.3390","volume":"8","author":[{"given":"Erin","family":"Oldenhof","sequence":"first","affiliation":[{"name":"School of Psychology, Deakin University, Geelong, VIC 3220, Australia"},{"name":"Reconnexion, Malvern East, Melbourne 3145, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4525-1834","authenticated-orcid":false,"given":"Jane","family":"Anderson-Wurf","sequence":"additional","affiliation":[{"name":"Reconnexion, Malvern East, Melbourne 3145, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Hall","sequence":"additional","affiliation":[{"name":"School of Psychology, Deakin University, Geelong, VIC 3220, Australia"},{"name":"Centre for Drug Use, Addictive and Anti-social Behaviour Research (CEDAAR), Deakin University, Geelong, VIC 3220, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6968-5015","authenticated-orcid":false,"given":"Petra K.","family":"Staiger","sequence":"additional","affiliation":[{"name":"School of Psychology, Deakin University, Geelong, VIC 3220, Australia"},{"name":"Centre for Drug Use, Addictive and Anti-social Behaviour Research (CEDAAR), Deakin University, Geelong, VIC 3220, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,12,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/jama.1973.03220410039008","article-title":"Psychotropic drugs in use today: The role of Diazepam in medical practice","volume":"225","author":"Blackwell","year":"1973","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2190\/FPJT-V9YE-VWM1-UXPA","article-title":"Increased prescribing of Valium, Librium, and other drugs: An example of the influence of economic and social factors on the practice of medicine","volume":"7","author":"Waldron","year":"1977","journal-title":"Int. J. Health Serv."},{"key":"ref_3","first-page":"245","article-title":"The use of Valium as a form of social control","volume":"15","author":"Koumjian","year":"1981","journal-title":"Soc. Sci. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/archpsyc.1973.01750360007002","article-title":"National patterns of psychotherapeutic drug use","volume":"28","author":"Parry","year":"1973","journal-title":"Arch. Gen. Psych."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00048678109159402","article-title":"Benzodiazepines\u2014Pancea or poison?","volume":"15","author":"Lader","year":"1981","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_6","unstructured":"Ashton, H. (2002). Benzodiazepines: How They Work & How to Withdraw, University of Newcastle."},{"key":"ref_7","unstructured":"Committee on Safety of Medicines (1988). Benzodiazepines, dependence and withdrawal symptoms. Curr. Probl., 21, 1\u20132."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00023210-200418010-00004","article-title":"Cognitive effects of long-term benzodiazepine use: A meta-analysis","volume":"18","author":"Barker","year":"2004","journal-title":"CNS Drugs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10072-016-2732-5","article-title":"Multifocal cognitive dysfunction in high-dose benzodiazepine users: A cross-sectional study","volume":"38","author":"Federico","year":"2017","journal-title":"Neurol. Sci."},{"key":"ref_10","first-page":"639","article-title":"A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs","volume":"29","author":"Tannenbaum","year":"2012","journal-title":"Drugs Aging"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.drugalcdep.2014.06.020","article-title":"Quality of life in a cohort of high-dose benzodiazepine dependent patients","volume":"142","author":"Lugoboni","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s11136-004-8745-1","article-title":"Use of tranquilizers and sleeping pills among cancer patients is associated with a poorer quality of life","volume":"13","author":"Paltiel","year":"2004","journal-title":"Qual. Life Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Tamburin, S., Federico, A., Faccini, M., Casari, R., Morbioli, L., Sartore, V., Mirijello, A., Addolorato, G., and Lugoboni, F. (2017). Determinants of quality of life in high-dose benzodiazepine misusers. Int. J. Environ. Res. Public Health, 14.","DOI":"10.3390\/ijerph14010038"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/NMD.0000000000000348","article-title":"Determinants of treatment-resistant depression: The salience of benzodiazepines","volume":"203","author":"Parker","year":"2015","journal-title":"J. Nerv. Ment. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0022-3999(94)90142-2","article-title":"Anxiety or depression during withdrawal of hypnotic treatments","volume":"38","author":"Lader","year":"1994","journal-title":"J. Psychosom. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/bcp.12224","article-title":"High dose benzodiazepines prolong reaction times in chronic users who have major depressive and\/or anxiety disorders","volume":"77","author":"Manthey","year":"2014","journal-title":"Br. J. Clin. Pharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.4088\/PCC.16r02037","article-title":"Prescribed benzodiazepines and suicide risk: A review of the literature","volume":"19","author":"Dodds","year":"2017","journal-title":"Prim. Care Companion CNS Disord."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.aap.2012.06.017","article-title":"Risk of road accident associated with the use of drugs: A systematic review and meta-analysis of evidence from epidemiological studies","volume":"60","author":"Elvik","year":"2013","journal-title":"Accid. Anal. Prev."},{"key":"ref_19","first-page":"64","article-title":"Sedative hypnotic medication use and the risk of motor vehicle crash","volume":"105","author":"Hansen","year":"2015","journal-title":"Res. Pract."},{"key":"ref_20","first-page":"437","article-title":"Effects of drug pharmacokinetic\/pharmacodynamic properties, characteristics of medication use, and relevant pharmacological interventions on fall risk in elderly patients","volume":"10","author":"Chen","year":"2014","journal-title":"Clin. Risk Manag."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40266-014-0159-3","article-title":"Use of benzodiazepines and association with falls in older people admitted to hospital: A prospective cohort study","volume":"31","author":"Ballokova","year":"2014","journal-title":"Drugs Aging"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.maturitas.2017.04.002","article-title":"Relationship between the use of benzodiazepines and falls in older adults: A systematic review","volume":"101","author":"Cano","year":"2017","journal-title":"Maturitas"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000454881","article-title":"Benzodiazepine use and risk of dementia in the elderly population: A systematic review and meta-analysis","volume":"47","author":"Islam","year":"2016","journal-title":"Neuroepidemiology"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Zhong, G., Wang, Y., Zhang, Y., and Zhao, Y. (2015). Association between benzodiazepine use and dementia: A meta-analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0127836"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e6231","DOI":"10.1136\/bmj.e6231","article-title":"Benzodiazepine use and risk of dementia: Prospective population based study","volume":"345","author":"Begaud","year":"2012","journal-title":"BMJ"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"g1996","DOI":"10.1136\/bmj.g1996","article-title":"Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: Retrospective cohort study","volume":"348","author":"Weich","year":"2014","journal-title":"BMJ"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1177\/070674371005500904","article-title":"Mortality hazard associated with anxiolytic and hypnotic drug use in the national population health survey","volume":"55","author":"Belleville","year":"2010","journal-title":"Can. J. Psychiatry"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/0004867415616695","article-title":"Mortality associated with anxiolytic and hypnotic drugs: A systematic review and meta-analysis","volume":"50","author":"Parsaik","year":"2016","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1177\/0004867414548902","article-title":"Benzodiazepine use and aggressive behaviour: A systematic review","volume":"48","author":"Albrecht","year":"2014","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1592\/phco.24.13.1177.38089","article-title":"Paradoxical reactions to benzodiazepines: Literature review and treatment options","volume":"24","author":"Mancuso","year":"2004","journal-title":"Pharmacotherapy"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.psychres.2017.09.059","article-title":"Prescribing practices in Southeastern Europe: Focus on benzodiazepine prescription at discharge from nine university psychiatric hospitals","volume":"258","author":"Maric","year":"2017","journal-title":"Psychiatry Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.psychres.2016.01.040","article-title":"Continuation and discontinuation of benzodiazepine prescriptions: A cohort study based on a large claims database in Japan","volume":"237","author":"Takeshima","year":"2016","journal-title":"Psychiatry Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40261-016-0397-8","article-title":"Benzodiazepine use, misuse, and harm at the population level in Canada: A comprehensive narrative review of data and developments since 1995","volume":"36","author":"Murphy","year":"2016","journal-title":"Clin. Drug Investig."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/bcpt.12684","article-title":"Long-term use of z-hypnotics and co-medication with benzodiazepines and opioids","volume":"120","author":"Sakshaug","year":"2017","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamapsychiatry.2014.1763","article-title":"Benzodiazepine use in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1590\/2237-6089-2015-0041","article-title":"Assessment of dependence and anxiety among benzodiazepine users in a provincial municipality in Rio Grande do Sul, Brazil","volume":"38","author":"Schallemberger","year":"2016","journal-title":"Trends Psychiatry Psychother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1111\/j.1360-0443.2011.03563.x","article-title":"Benzodiazepines revisited: Will we ever learn?","volume":"106","author":"Lader","year":"2011","journal-title":"Addiction"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/0897190013515001","article-title":"Benzodiazepines: A major component in unintentional prescription drug overdoses with opioid analgesics","volume":"27","author":"Jann","year":"2014","journal-title":"J. Pharm. Pract."},{"key":"ref_39","unstructured":"Liew, D., Joules, E., Booth, J., Garrett, K., and Fauman, A. (2017). Evidence to Inform the Inclusion of Schedule 4 Prescription Medications on a Real-Time Prescription Monitoring System, Austin Health."},{"key":"ref_40","unstructured":"NIH: National Institute on Drug Abuse (2019, November 27). Overdose Death Rates, Available online: https:\/\/www.drugabuse.gov\/related-topics\/trends-statistics\/overdose-death-rates."},{"key":"ref_41","unstructured":"National Records of Scotland (2019). Drug related deaths in. Scotland in 2018, National Records of Scotland."},{"key":"ref_42","unstructured":"Office for National Statistics (2019). Statistical Bulletin: Deaths Related to Drug Poisoning in England and Wales: 2018 Registrations, Office for National Statistics."},{"key":"ref_43","unstructured":"Statistics Canada (2019, October 03). Causes of Death. Available online: https:\/\/www150.statcan.gc.ca\/n1\/daily-quotidien\/190530\/dq190530c-eng.htm."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Gravensteen, I.K., Ekeberg, O., Thiblin, I., Helweg-Larsen, K., Hem, E., Rogde, S., and Tollefsen, I.M. (2019). Psychoactive substances in natural and unnatural deaths in Norway and Sweden: A study on victims of suicide and accidents compared with natural deaths in psychiatric patients. BMC Psychiatry, 19.","DOI":"10.1186\/s12888-019-2015-9"},{"key":"ref_45","unstructured":"PDMP Center of Excellence at Brandeis University (2019, October 02). Briefing on PDMP effectiveness. Available online: https:\/\/www.pdmpassist.org\/pdf\/Resources\/Briefing%20on%20PDMP%20Effectiveness%203rd%20revision.pdf."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Finley, E.P., Garcia, A., Rosen, K., McGeary, D., Pugh, M.J., and Potter, J.S. (2017). Evaluating the impact of prescription drug monitoring program implementation: A scoping review. BMC Health Serv. Res., 17.","DOI":"10.1186\/s12913-017-2354-5"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"783","DOI":"10.7326\/M17-3074","article-title":"Association between prescription drug monitoring programs and nonfatal and fatal drug overdoses: A systematic review","volume":"168","author":"Fink","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jpain.2017.10.001","article-title":"Association of prescription drug monitoring program use with opioid prescribing and health outcomes: A comparison of program users and nonusers","volume":"19","author":"Deyo","year":"2018","journal-title":"J. Pain"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugalcdep.2014.10.001","article-title":"What we know, and don\u2032t know, about the impact of state policy and systems-level interventions on prescription drug overdose","volume":"145","author":"Haegerich","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/pam.22098","article-title":"Mandatory access prescription drug monitoring programs and prescription drug abuse","volume":"38","author":"Grecu","year":"2018","journal-title":"J. Policy Anal. Manag."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/dar.12959","article-title":"Prescription drug monitoring programs and drug overdose deaths involving benzodiazepines and prescription opioids","volume":"38","author":"Liang","year":"2019","journal-title":"Drug Alcohol Rev."},{"key":"ref_52","unstructured":"PDMP Center of Excellence at Brandeis University (2019, October 02). PDMP Prescriber Use Mandates: Characteristics, Current Status, and Outcomes in Selected States. Available online: http:\/\/www.pdmpassist.org\/pdf\/Resources\/Briefing_on_mandates_3rd_revision_A.pdf."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jama.2014.18514","article-title":"Mandatory use of prescription drug monitoring programs","volume":"313","author":"Haffajee","year":"2015","journal-title":"JAMA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"48","DOI":"10.18773\/austprescr.2019.007","article-title":"Real-time prescription monitoring: Lessons from Tasmania","volume":"42","author":"Boyles","year":"2019","journal-title":"Aust. Prescr."},{"key":"ref_55","first-page":"17","article-title":"Clinical care and regulation of opioid use: The Tasmanian model","volume":"183","author":"Reynolds","year":"2017","journal-title":"Med. Today"},{"key":"ref_56","first-page":"1","article-title":"The opioid epidemic in North America: Implications for Australia","volume":"578","author":"Brown","year":"2019","journal-title":"Trends Issues Crime Crim. Justice"},{"key":"ref_57","unstructured":"State Government of Victoria (2019, October 02). Real-Time Prescription Monitoring, Available online: http:\/\/www2.health.vic.gov.au\/public-health\/drugs-and-poisons\/real-time-prescription-monitoring."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1300\/J088v04n03_02","article-title":"The influence of multiple copy prescription programs on analgesic utilization","volume":"4","author":"Wastila","year":"1996","journal-title":"J. Pharm. Care Pain Symptom Control"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1526-4637.2004.04049.x","article-title":"Regulating opioid prescribing through prescription monitoring programs: Balancing drug diversion and treatment of pain","volume":"5","author":"Fishman","year":"2004","journal-title":"Pain Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1526-4637.2011.01062.x","article-title":"Prescription drug monitoring programs and death rates from drug overdose","volume":"12","author":"Paulozzi","year":"2011","journal-title":"Pain Med."},{"key":"ref_61","first-page":"39","article-title":"Policies for deprescribing: An international scan of intended and unintended outcomes of limiting sedative-hypnotic use in community-dwelling older adults","volume":"14","author":"Shaw","year":"2019","journal-title":"Healthc. Policy"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.1991.03470170080028","article-title":"Consequences of the 1989 New York state triplicate benzodiazepine prescription regulations","volume":"266","author":"Weintraub","year":"1991","journal-title":"JAMA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.sapharm.2013.06.008","article-title":"The effect of the Medicare Part D benzodiazepine exclusion on the utilization patterns of benzodiazepines and substitute medications","volume":"10","author":"Chen","year":"2014","journal-title":"Res. Soc. Adm. Pharm."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e1911590","DOI":"10.1001\/jamanetworkopen.2019.11590","article-title":"Comparison of prescribing patterns before and after implementation of a national policy to reduce inappropriate Alprazolam prescribing in Australia","volume":"2","author":"Schaffer","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s13181-012-0273-8","article-title":"Windmills and pill mills: Can PDMPs tilt the prescription drug epidemic?","volume":"8","author":"Gugelmann","year":"2012","journal-title":"J. Med. Toxicol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1056\/NEJMp1204493","article-title":"Medication reconciliation for controlled substances: An \u201cideal\u201d prescription-drug monitoring program","volume":"366","author":"Perrone","year":"2012","journal-title":"New. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2190\/8FR4-QYY1-7MYG-2AGJ","article-title":"A controlled study of the effects of state surveillance on indicators of problematic and non-problematic benzodiazepine use in a medicaid population","volume":"34","author":"Brown","year":"2004","journal-title":"Int. J. Psychiatry Med."},{"key":"ref_68","first-page":"65","article-title":"Benefits and challenges to the implementation of real-time prescription monitoring","volume":"16","author":"Ogeil","year":"2015","journal-title":"Med. Today"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2050-6511-15-46","article-title":"An inevitable wave of prescription drug monitoring programs in the context of prescription opioids: Pros, cons and tensions","volume":"15","author":"Islam","year":"2014","journal-title":"BMC Pharm. Toxicol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.drugalcdep.2014.10.005","article-title":"Observed transition from opioid analgesic deaths toward heroin","volume":"145","author":"Dasgupta","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Unick, G.J., Rosenblum, D., Mars, S., and Ciccarone, D. (2013). Intertwined epidemics: National demographic trends in hospitalizations for heroin- and opioid-related overdoses, 1993\u20132009. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0054496"},{"key":"ref_72","first-page":"297","article-title":"State prescription drug monitoring programs and fatal drug overdoses","volume":"23","author":"Nam","year":"2017","journal-title":"Am. J. Manag. Care"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1093\/pm\/pnw019","article-title":"Clinical styles and practice policies: Influence on communication with patients regarding worrisome prescription drug monitoring program data","volume":"17","author":"Hildebran","year":"2016","journal-title":"Pain Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/10826084.2018.1491052","article-title":"Perceived Unintended Consequences of Prescription Drug Monitoring Programs","volume":"54","author":"Smith","year":"2019","journal-title":"Subst. Use Misuse"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1176\/ajp.141.12.1606","article-title":"Seizures induced by abrupt discontinuation from Alprazolam","volume":"141","author":"Breier","year":"1984","journal-title":"Am. J. Psychiatry"},{"key":"ref_76","unstructured":"American Psychiatric Association (1990). Benzodiazepine Dependence, Toxicity, and Abuse, APA."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archpsyc.1990.01810220015002","article-title":"Long term therapeutic use of benzodiazepines- I. Effects of abrupt discontinuation","volume":"47","author":"Rickels","year":"1990","journal-title":"Arch. Gen. Psych."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0740-5472(91)90023-4","article-title":"Protracted withdrawal syndromes from benzodiazepines","volume":"8","author":"Ashton","year":"1991","journal-title":"J. Subst. Abus. Treat."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.drugpo.2015.08.005","article-title":"Prescription monitoring programs and emergency department visits involving benzodiazepine misuse: Early evidence from 11 United States metropolitan areas","volume":"28","author":"Bachhuber","year":"2016","journal-title":"Int. J. Drug Policy"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.drugalcdep.2015.11.010","article-title":"Prevalence, prescribed quantities, and trajectory of multiple prescriber episodes for benzodiazepines: A 2-year cohort study","volume":"158","author":"Okumura","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"ref_81","first-page":"7","article-title":"The intended and unintended consequences of benzodiazepine monitoring programmes: A review of the literature","volume":"37","author":"Fisher","year":"2012","journal-title":"J. Clin. Pharm."},{"key":"ref_82","unstructured":"Dwyer, J. (2019, October 05). New Insights into Victorian Pharmaceutical Drug Overdose Death. Available online: https:\/\/www.turningpoint.org.au\/education\/talking-point\/victorian-pharmaceutical-drug-overdose-death."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Allen, B., Harocopos, A., and Chernick, R. (2019). Substance use stigma, primary care, and the New York state prescription drug monitoring program. Behav. Med., in press.","DOI":"10.1080\/08964289.2018.1555129"},{"key":"ref_84","first-page":"1063","article-title":"Clinicians\u2032 use of prescription drug monitoring programs in clinical practice and decision-making","volume":"18","author":"Leichtling","year":"2017","journal-title":"Pain Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1056\/NEJMra1611832","article-title":"Treatment of Benzodiazepine Dependence","volume":"376","author":"Soyka","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11920-016-0668-3","article-title":"Long-term pharmacological treatments of anxiety disorders: An updated systematic review","volume":"18","author":"Perna","year":"2016","journal-title":"Curr. Psychiatry Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/fampra\/cmt010","article-title":"Tolerance to benzodiazepines among long-term users in primary care","volume":"30","author":"Willems","year":"2013","journal-title":"Fam. Pr."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.drugalcdep.2019.02.033","article-title":"The epidemiology of benzodiazepine misuse: A systematic review","volume":"200","author":"Votaw","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1526-4637.2011.01117.x","article-title":"Police officer, deal-maker, or health care provider? Moving to a patient-centered framework for chronic opioid management","volume":"12","author":"Nicolaidis","year":"2011","journal-title":"Pain Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"152","DOI":"10.18773\/austprescr.2015.055","article-title":"Management of benzodiazepine misuse and dependence","volume":"38","author":"Brett","year":"2015","journal-title":"Aust. Prescr."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1111\/j.1526-4637.2010.00980.x","article-title":"The patient\u2013provider relationship in chronic pain care: Providers\u2032 perspectives","volume":"11","author":"Matthias","year":"2011","journal-title":"Pain Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"399","DOI":"10.36076\/ppj.2007\/10\/399","article-title":"National drug control policy and prescription drug abuse: Facts and fallacies","volume":"10","author":"Manchikanti","year":"2007","journal-title":"Pain Physician"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0277-9536(99)00376-7","article-title":"Doctor-patient communication about drugs: The evidence for shared decision making","volume":"50","author":"Stevenson","year":"2000","journal-title":"Soc. Sci. Med."},{"key":"ref_94","first-page":"892","article-title":"Shared decision making and the concept of equipoise: The competences of involving patients in healthcare choices","volume":"50","author":"Elwyn","year":"2000","journal-title":"Br. J. Gen. Pract."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s11606-019-04983-y","article-title":"Setting expectations, following orders, safety, and standardization: Clinicians\u2032 strategies to guide difficult conversations about opioid prescribing","volume":"34","author":"Wyse","year":"2019","journal-title":"J. Gen. Intern. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dar.12195","article-title":"Implementing real-time prescription drug monitoring: Are we ready?","volume":"33","author":"Nielsen","year":"2014","journal-title":"Drug Alcohol Rev."},{"key":"ref_97","unstructured":"The Royal Australian College of General Practitioners (2015). Prescribing Drugs of Dependence in General Practice, Part B\u2014Benzodiazepines, The Royal Australian College of General Practitioners."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0277-9536(00)00098-8","article-title":"Patient-centredness: A conceptual framework and review of the empirical literature","volume":"51","author":"Mead","year":"2000","journal-title":"Soc. Sci. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0272-7358(02)00146-0","article-title":"A review of therapist characteristics and techniques positively impacting the therapeutic alliance","volume":"23","author":"Ackerman","year":"2003","journal-title":"Clin. Psychol. Rev."},{"key":"ref_100","unstructured":"Oldenhof, E., Hall, K., Youssef, G., and Staiger, P.K. (2019). Influences on Long-Term Benzodiazepine Users Decision to Continue or Stop Taking Their Medication, Deakin University."},{"key":"ref_101","unstructured":"American Psychiatric Association (2009). Practice Guideline for the Treatment of Patients with Panic Disorder, American Psychiatric Association Publishing."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1037\/0003-066X.47.9.1102","article-title":"In search of how people change: Applications to addictive behaviors","volume":"47","author":"Prochaska","year":"1992","journal-title":"Am. Psychol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1037\/0022-006X.74.5.908","article-title":"Benzodiazepine discontinuation among adults with GAD: A randomized trial of cognitive-behavioral therapy","volume":"74","author":"Gosselin","year":"2006","journal-title":"J. Consult. Clin. Psychol"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1360-0443.2008.02364.x","article-title":"Effectiveness of current treatment approaches for benzodiazepine discontinuation: A meta-analysis","volume":"104","author":"Parr","year":"2009","journal-title":"Addiction"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.brat.2010.04.002","article-title":"Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: Further evaluation","volume":"48","author":"Otto","year":"2010","journal-title":"Behav. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brat.2003.12.002","article-title":"Long-term outcome after discontinuation of benzodiazepines for insomnia: A survival analysis of relapse","volume":"43","author":"Morin","year":"2005","journal-title":"Behav. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1037\/0022-006X.67.1.151","article-title":"Cognitive-behavioral therapy helps prevent relapse and recurrence of panic disorder following Alprazolam discontinuation: A long-term follow-up of the Peoria and Dartmouth studies","volume":"67","author":"Bruce","year":"1999","journal-title":"J. Consult. Clin. Psychol."},{"key":"ref_108","unstructured":"Wurf, G., O\u2032Neal, P., Swing, A., and Golin, R. (2019). A Mixed Methods Evaluation of the Reconnexion Benzodiazepine Support and Counselling Service, Monash University."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Creupelandt, H., Anthierens, S., Habraken, H., Sirdifield, C., Niroshan Siriwardena, A., and Christiaens, T. (2019). A tailored e-learning gives long-term changes in determinants of GPs\u2032 benzodiazepines prescribing: A pretest-posttest study with self-report assessments. Scand. J. Prim. Health Care, 1\u20138.","DOI":"10.1080\/02813432.2019.1663591"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/pm\/pnv083","article-title":"You present like a drug addict: Patient and clinician perspectives on trust and trustworthiness in chronic pain management","volume":"17","author":"Buchman","year":"2016","journal-title":"Pain Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1176\/appi.ps.201600056","article-title":"Social stigma toward persons with prescription opioid use disorder: Associations with public support for punitive and public health-oriented policies","volume":"68","author":"Barry","year":"2017","journal-title":"Psychiatr. Serv."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.socscimed.2005.07.016","article-title":"Views of general practitioners and benzodiazepine users on benzodiazepines: A qualitative analysis","volume":"62","author":"Parr","year":"2006","journal-title":"Soc. Sci. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/jep.12756","article-title":"Safer and more appropriate opioid prescribing: A large healthcare system\u2032s comprehensive approach","volume":"23","author":"Losby","year":"2017","journal-title":"J. Eval. Clin. Pract."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/12\/2143\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:40:09Z","timestamp":1760190009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/12\/2143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,4]]},"references-count":113,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["jcm8122143"],"URL":"https:\/\/doi.org\/10.3390\/jcm8122143","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,4]]}}}